Prenetics Global (NasdaqGM:PRE) opened 2026 with Q1 revenue of about US$36 million and a basic EPS loss of US$1.61, while trailing twelve month revenue stood at roughly US$120 million alongside a basic EPS loss of US$3.71. Over recent quarters, revenue has shifted from US$17.31 million in Q1 2025 to US$36.56 million in Q4 2025 and US$35.95 million in Q1 2026, with quarterly basic EPS losses ranging from US$0.80 to US$1.61 over the same stretch. As a result, the spotlight is now firmly on how efficiently that top line can be converted into healthier margins.

See our full analysis for Prenetics Global.

With the headline numbers on the table, the next step is to see how this earnings print aligns with the key narratives investors have been following and where the latest figures start to challenge those stories.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Losses Widen To US$27.3 Million Despite Higher Sales

• Q1 2026 net loss excluding extra items came in at US$27.3 million compared with US$9.7 million in Q4 2025, while trailing twelve month net loss excluding extra items was US$55.9 million on US$120.1 million of revenue.
• Analysts' consensus narrative leans on the idea that IM8’s subscription model and rising average order value can help margins over time, yet the Q1 2026 figures show losses that are still large relative to the US$35.95 million in quarterly revenue.
  • The consensus view highlights a path toward stronger earnings based on operating leverage. However, the gap between US$120.1 million of trailing revenue and the US$55.9 million trailing loss shows that profitability remains some distance away.
  • Investors following the consensus story may want to pay close attention to how quickly IM8’s 80% subscription base translates into better net margins as opposed to just higher top line.

Premium P/S Multiple With Mixed Profit Profile

• Prenetics trades on a P/S of 2.7x, above both the cited peer average of 2.0x and the US Healthcare industry average of 1.2x, while the company remains unprofitable on a trailing basis.
• Bears point to the rich P/S multiple and ongoing losses as reasons to be cautious, and the data here gives them several talking points.
  • Trailing twelve month basic EPS is a loss of US$3.71 and net income excluding extra items is a loss of US$55.9 million, so the higher P/S multiple is not backed by positive earnings at this stage.
  • Shareholders have also seen dilution over the past year, which means any future improvement in earnings will be spread across a larger share count.

For readers who want to see how skeptics frame these issues around valuation and profitability in more depth, there is a dedicated bear case narrative for the stock: 🐻 Prenetics Global Bear Case

DCF Fair Value And Analyst Target Signal Upside

• The provided DCF fair value of US$225.40 and analyst price target of US$31.25 both sit well above the current share price of US$19.25, even as the business reported a trailing twelve month loss of US$55.9 million.
• Bulls argue that strong forecast revenue growth of about 51.5% per year can help close the gap between today’s price and those valuation markers, and the recent revenue run rate gives some support to that view.
  • Trailing twelve month revenue of US$120.1 million compares with only US$15.9 million in the period ending Q4 2024, which is the kind of acceleration bulls link to the IM8 brand ramping up.
  • The bullish narrative also points to IM8’s projected annual recurring revenue targets and the company’s reported liquidity of more than US$120 million as reasons it can keep investing behind growth while working toward better margins.

Supporters of the bullish view often focus on how rapidly scaling IM8 could justify both the DCF fair value and the analyst target, and you can see how they connect those dots in the dedicated bull case narrative: 🐂 Prenetics Global Bull Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Prenetics Global on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this mix of risks and potential rewards leaves you undecided, move quickly to check the underlying data and weigh the 3 key rewards and 2 important warning signs.

See What Else Is Out There

Prenetics is still reporting sizable losses alongside a premium P/S multiple and shareholder dilution, so profitability and valuation support are not yet lining up.

If that mix of ongoing losses and rich pricing makes you uneasy, it can be worth comparing with companies that screen as 63 resilient stocks with low risk scores before you commit fresh capital.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.